Your shopping cart is currently empty

Mizagliflozin is an orally active, selective SGLT1 inhibitor with a Ki value of 27 nM for human SGLT1. Mizagliflozin is 303 times more selective for SGLT1 than for SGLT2. Mizagliflozin is an anti-diabetic drug that can improve postprandial blood sugar fluctuations and may have the potential to improve chronic constipation.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $61 | In Stock | In Stock | |
| 2 mg | $88 | In Stock | In Stock | |
| 5 mg | $147 | In Stock | In Stock | |
| 10 mg | $239 | In Stock | In Stock | |
| 25 mg | $479 | In Stock | In Stock | |
| 50 mg | $679 | In Stock | In Stock | |
| 100 mg | $987 | In Stock | In Stock | |
| 200 mg | $1,330 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $183 | In Stock | In Stock |
| Description | Mizagliflozin is an orally active, selective SGLT1 inhibitor with a Ki value of 27 nM for human SGLT1. Mizagliflozin is 303 times more selective for SGLT1 than for SGLT2. Mizagliflozin is an anti-diabetic drug that can improve postprandial blood sugar fluctuations and may have the potential to improve chronic constipation. |
| Targets&IC50 | SGLT1 (human):(ki)27 nM, SGLT2 (human):8170 nM(ki) |
| In vivo | METHODS: Mizagliflozin (GSK-1614235 free base) (0.3 mg/kg, intravenous administration) and oral administration (3 mg/kg, oral administration) were administered to rats to study its pharmacokinetics and metabolite profile. RESULTS Mizagliflozin had different half-lives in rats (0.23 and 1.14 hours, respectively) depending on the administration route; the absolute bioavailability was only 0.02%; after oral administration, Mizagliflozin was mainly metabolized to its aglycone KP232 in the intestine. [2] |
| Synonyms | KGA-3235 free base, GSK-1614235 free base, DSP-3235 free base |
| Molecular Weight | 564.67 |
| Formula | C28H44N4O8 |
| Cas No. | 666843-10-3 |
| Smiles | CC(C)c1[nH]nc(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)c1Cc1ccc(OCCCNCC(C)(C)C(N)=O)cc1C |
| Relative Density. | 1.274 g/cm3 (Predicted) |
| Storage | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | Methanol: 250 mg/mL (442.74 mM), Sonication is recommended. DMSO: 100 mg/mL (177.09 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (7.08 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO/Methanol
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.